Introduction
Receptor protein tyrosine phosphatases (RPTPs) are transmembrane proteins implicated in the regulation of axon growth and guidance (Bixby, 2000; Johnson and Van Vactor, 2003) . In particular, genetic evidence implicates type IIa and type III RPTPs in pathway selection by photoreceptors, CNS axons, and motor neurons in Drosophila (Van Vactor et al., 1998; Newsome et al., 2000; Clandinin et al., 2001; Maurel-Zaffran et al., 2001; Schindelholz et al., 2001; Sun et al., 2001) . The low penetrance of defects in RPTP null mutants, and similarities in phenotypes between null mutants of different RPTPs, suggest redundancy in RPTP function during axonogenesis. However, examination of multiple mutants indicates both cooperation and competition among RPTPs in guiding axons (Desai et al., 1997; Schindelholz et al., 2001 ).
Evidence of RPTP function in vertebrate axon pathfinding is less clear. In vitro evidence links the vertebrate type IIa RPTPs leukocyte common-antigen-related (LAR), protein tyrosine phosphatase (PTP)-␦, and PTP-to axon growth regulation (Ledig et al., 1999b; Wang and Bixby, 1999 ; Q. L. Yang et al., 2003) , and similar evidence has been obtained for the type III RPTP, PTP receptor type O (PTPRO) (Stepanek et al., 2001) . Experiments using putative dominant-negative mutants of PTP-and PTP-␦ suggest involvement of these RPTPs in pathfinding in vivo (Johnson et al., 2001; Rashid-Doubell et al., 2002) . LAR, PTP-␦, and PTP-mutant mice have nervous system phenotypes, some of which may be related to axon growth (Yeo et al., 1997; Elchebly et al., 1999; Wallace et al., 1999; Uetani et al., 2000) . Finally, LAR and PTP-null mutants exhibit aberrant peripheral nerve regeneration (Xie et al., 2001; McLean et al., 2002; Thompson et al., 2003; Van der Zee et al., 2003) . Direct loss-of-function experiments linking these RPTPs to developmental axon guidance have not been reported.
The routes taken by embryonic motor axons to their targets are relatively well understood. In the chick spinal cord, axons from different motor pools are intermingled, because they grow toward a "choice point" at the base of the limb; there, axons segregate and extend dorsally or ventrally (Landmesser, 1978b ; Lance-Jones and Landmesser, 1981) . In the limb, axons diverge again to grow to their proper target muscles (Lance-Jones and Landmesser, 1981; Tosney and Landmesser, 1985) . Type IIa and type III RPTPs are involved in decision making at motor neuron choice points in Drosophila, and these functions may be conserved. Because several such RPTPs are expressed in embryonic chick motor neurons, these neurons should be a useful system for examining the roles of RPTPs in vertebrate axon guidance.
In the chick, RNA interference (RNAi) can be combined with in ovo electroporation to knock down expression of guidance proteins in the developing spinal cord (Pekarik et al., 2003) . We used this methodology to perform loss-of-function experiments for PTP-␦, PTP-, and PTPRO in developing spinal motor neurons. Our studies provide the first evidence for the involvement of a vertebrate type III RPTP in axon growth in vivo, and support the idea of cooperation and competition among vertebrate RPTPs in regulation of motor axon pathfinding.
Materials and Methods
Materials. Fertilized White Leghorn chicken eggs were purchased from SPAFAS (Norwich, CT) and incubated in a humidified incubator at 38°C until the desired stage of development. All of the chemicals were purchased from Sigma (St. Louis, MO) unless stated otherwise.
In situ hybridization. Plasmids containing cDNA for base pairs 382-1004 of chick (c)PTPRO (accession number U65891), base pairs 1093-1489 of cPTP-(accession number L32780), and a portion of cPTP-␦ that aligns to base pairs 877-1478 of human PTP-␦ (accession number L38929) were linearized and used as templates for transcription of sense and antisense digoxygenin-labeled riboprobes using the recommended procedure (Roche, Mannheim, Germany). Embryos were dissected at embryonic day 5.5 (E5.5), fixed in 4% paraformaldehyde overnight, cryoprotected in 30% sucrose overnight, and frozen in OCT (Tissue Tek; Fisher Scientific, Pittsburgh, PA) for cryosectioning. Ten-micrometer-thick sections were allowed to dry and processed for in situ hybridization following a standard protocol (Schaeren-Wiemers and Gerfin-Moser, 1993) . Sections were hybridized overnight with 600 ng/ml riboprobe at 56°C.
Production of double-stranded RNA. Sense and antisense RNAs were produced from plasmids encoding portions of cPTP-(base pairs 1093-1489), cPTP-␦ (aligns to base pairs 877-1478 of human PTP-␦), cPTPRO (base pairs 1458 -2334), and cChAT (base pairs 1344 -1665; accession number AY044155). After linearization with the appropriate restriction endonucleases, RNA was transcribed using the SP6 and T7 MegaScript kits from Ambion (Austin, TX). RNA was cleaned, analyzed, and annealed as described previously (Pekarik et al., 2003) .
In ovo RNA interference. Double-stranded RNA (dsRNA) injection and electroporation were performed as described previously (Pekarik et al., 2003) . Embryos were injected at E3 to E3.5 and dissected 48 -60 h later . dsRNA for combinatorial RNA interference (RNAi) was injected at a final concentration of 500 ng/l for each RNA. This gave molarities of 1.7 M for PTP-, 1.1 M for PTP-␦, 0.8 M for PTPRO, and 2.0 M for choline acetyltransferase (ChAT).
Western blotting. Embryos were dissected 48 h postelectroporation in cold PBS-glucose. The lumbosacral portions of 10 -15 spinal cords were split into right and left sides and lysed in 1% Igepal CA-630, 5 mM EDTA, 100 g/ml PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotinin, and 1 mg/ml pepstatin A in TBS (25 mM Tris, 150 mM NaCl, pH 7.4) for 30 min. Undissolved pellets were cleared by centrifugation (12,000 ϫ g; 30 min), and 50 g of supernatant protein was separated on SDS-PAGE and transferred to nitrocellulose as described previously (Bixby and Jhabvala, 1990) . Primary antibodies were rabbit anti-cPTPRO (Ledig et al., 1999a) at 1:2500, or rabbit anti-cPTP- (Stoker et al., 1995) at 1:5000. Secondary antibody was Alexa Fluor 680 goat anti-rabbit IgG (Molecular Probes, Eugene, OR). After rinsing, blots were incubated with anti-chick L1 cell adhesion molecule (L1CAM) (Lemmon and McLoon, 1986) , followed by infrared dye 800-conjugated anti-mouse IgG (Rockland, Gilbertsville, PA). Bound antibody was visualized, and band intensity was quantified using the LI-COR (Lincoln, NE) Odyssey Infrared Imaging System.
Whole-mount embryo staining. Embryos were dissected and fixed in 4% paraformaldehyde overnight. After rinsing in PBS, embryos were incubated in 1% Triton X-100 for 1 h, followed by 20 mM lysine in 0. 1,1Ј-Dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate tracing. After dissection, embryos were stored in 4% paraformaldehyde. For retrograde tracing, nitrocellulose membrane was soaked with a 1 mg/g dimethylformamide solution of 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate (DiI) (D-282; Molecular Probes) and allowed to dry. Small pieces of nitrocellulose were inserted into the limb bud in the termination zone of the AITIB.Embryoswerestoredat37°Cfor5d.Aftertracingwascomplete,embryos were embedded in 6.25% agar type IX, and 250 m transverse sections were cut on an oscillating tissue slicer (Electron Microscopy Sciences, Ft. Washington, PA). Anterograde tracing was performed on 250 m sections cut in the same way. The untreated side of the embryo was marked with india ink. Glass capillaries with a tip diameter of ϳ5 m were dipped into 5 mg/ml DiI dissolved in ethanol and placed into the ventrolateral spinal cord. After 1 h, capillaries were removed, and the sections were stored in the dark at room temperature for 7 d. Images were scanned using a Zeiss (Oberkochen, Germany) LSM510 confocal microscope (Miami Project to Cure Paralysis), and manipulated in Adobe Photoshop.
Islet-2 staining and design-based stereology. Embryos were dissected and fixed at 4°C for 1.5 h. Every fifth section of 20 m cryostat sections from the rostral lumbosacral region was processed for Islet-2 (Isl-2) immunohistochemistry. The Islet-2 primary antibody (51.4H9) developed by T. M. Jessell (Columbia University, New York, NY) was obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA) developed under the auspices of the National Institute of Child Health and Human Development and maintained by the University of Iowa (Iowa City, IA). Sections were incubated in a 1:100 dilution of 51.4H9 at 4°C for 48 h. After rinsing, they were incubated in a 1:1000 dilution of biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA). Bound antibody was visualized with the Vectastain Elite ABC kit (Vector Laboratories) followed by a nickel-intensified DAB reaction. Stereo Investigator 5.05.04 (MicroBrightField) was used to estimate the number of Islet-2-positive cells through the volume of the sectioned area. DAB-positive cells were counted in the right and left ventral horns of each section using a counting frame of 25 ϫ 25 m and a scan grid size of 45 ϫ 45 m. At least 300 cells on each side were counted per embryo. From this, the software estimated upward of 5000 Isl-2-positive cells per side of each embryo in the sectioned region.
PTPRO-GFP (green fluorescent protein) electroporation. PCR was used to add a unique SalI site at base pair 3100 just 3Ј of the sequence encoding the 28-aa juxtamembrane region of cPTPRO. The entire extracellular domain, transmembrane region, and juxtamembrane region were cloned into the pEGFP-N2 vector (Clontech, Palo Alto, CA) in-frame with the GFP-coding sequence. This cPTPRO-GFP construct was released from the pEGFP vector and cloned into a modified pIRES plasmid with a ␤-actin promoter (Pekarik et al., 2003) . PTPRO-GFP was electroporated with dsChAT RNA or dsPTPRO RNA at a final concentration of 1.5 g/l. After 48 h, embryos were dissected and 100 m sections of the lumbosacral segments were cut on an oscillating tissue slicer as described above. All of the in-focus green cells were counted in each section, and at least 10 sections were examined per embryo.
Statistics. Statistics were done using InStat (version 2.03).
Results

RPTPs are expressed in the lateral motor column of the embryonic chick spinal cord
The pathways taken by chick motor axons to their targets in the hindlimb are well understood, and the motor neurons are accessible for embryonic manipulation. We therefore chose to examine regulation of motor axon growth in the chick lumbosacral spinal cord. Two type IIa RPTPs, PTP-␦ and PTP-, and one type III RPTP, PTPRO, are expressed during the period of axon outgrowth in motor columns of the rodent spinal cord and the chick brachial spinal cord (Yan et al., 1993; Sommer et al., 1997; Chilton and Stoker, 2000; Beltran et al., 2003; Thompson et al., 2003) . To determine whether these RPTPs are also expressed in chick lumbosacral motor neurons, we performed in situ hybridization using digoxygenin-labeled riboprobes. PTPRO mRNA was expressed in the ventral horn, including large neurons, and in the dorsolateral commissural neurons ( Fig. 1 ) as well as in the dorsal root ganglia (data not shown) of E5 chick embryos. This is fully consistent with the pattern seen previously in the brachial spinal cord (Chilton and Stoker, 2000) . PTP-␦ mRNA was expressed diffusely throughout the lumbar spinal cord, including the ventral horn, and PTP-mRNA was found in the ventral horn and in the ventricular zone (data not shown). This pattern of mRNA expression is consistent with our hypothesis that these three RPTPs are involved in the growth of hindlimb motor axons from the embryonic chick spinal cord.
Electroporation of dsRNA specifically "knocks down" protein levels of target RPTP To assess the roles of RPTPs in motor axon guidance, we used in ovo electroporation combined with RNAi. Electroporation of long dsRNAs has been shown to produce specific and reproducible decreases in expression of target proteins (Pekarik et al., 2003) . The phenotypes resulting from gene silencing by RNAi are specific, in the sense that dsRNA targeting of known axonal guidance proteins produces the same axonal pathfinding defects as injection of cognate function-blocking antibodies, and expression levels of nontargeted proteins from the same family as the targeted protein are not changed (Stoeckli and Landmesser, 1995; Pekarik et al., 2003) . Recently, in ovo electroporation of short interfering RNA (siRNA) hairpins was shown to successfully knock down neuropilin-1 in the chick spinal cord (Bron et al., 2004) . Although this methodology is advantageous in that interfering RNA is continuously produced, using one long (400 -800 bp) dsRNA allowed us to sidestep issues of sequence selection, which is important because siRNAs differ in their effectiveness (Elbashir et al., 2001; Holen et al., 2002) . We produced dsRNAs targeting the type III RPTP, PTPRO, and the type IIa RPTPs, PTP-␦ and PTP-. These dsRNAs were injected into the central canal of E3.5 chick spinal cords and electroporated into the lumbosacral region. Because the electroporation confines transfection to one side of the spinal cord (Pekarik et al., 2003) (data not shown), this side will be referred to as the "treated" side; the other side acts as a control. After electroporation, the chicks were allowed to develop for 48 h. During this time period, motor neurons extend axons into the periphery (Hamburger, 1975; Oppenheim and Heaton, 1975) . We evaluated the efficacy of gene silencing by RNAi in two ways, using PTPRO as our test protein. In an initial series of experiments, we combined in ovo electroporation with coinjection of (1) a plasmid encoding a GFP fusion protein containing the extracellular, transmembrane, and juxtamembrane domains of PTPRO, and (2) dsRNA targeting either PTPRO or ChAT as a control. This allowed us to use GFP fluorescence to evaluate any change in transfected PTPRO expression attributable to dsRNAi. In embryos transfected with PTPRO-GFP and dsRNA targeting ChAT, a large number of GFP-expressing cells was always observed (Fig. 2 B) . In contrast, many fewer GFP-positive cells were observed after cotransfection of dsRNA targeting PTPRO (Fig.  2 D) . This effect was quantified by counting the number of GFPpositive cells per section in the two conditions. On average, we found 18.6 Ϯ 1.8 (mean Ϯ SEM) green fluorescent cells per section in the embryos cotransfected with ChAT dsRNA, compared with 1.4 Ϯ 0.3 cells per section with PTPRO dsRNA (n ϭ 3 embryos in each group; p Ͻ 0.0001). This drastic decrease in PTPRO-GFP expression was apparent throughout the electroporated region; there was no evidence that a subset of cells was more sensitive to electroporation or RNAi.
These experiments demonstrate that our dsRNA can effectively target PTPRO, but do not resolve the extent to which endogenous PTPRO is affected. Because our cPTPRO antibody is ineffective in immunohistochemistry, we examined this issue by Western blotting. The lumbosacral spinal cords from 10 -15 embryos were dissected and split into left and right halves, lysed, separated on SDS-PAGE, and probed with antibodies to RPTPs on Western blots. When we examined PTPRO expression in embryos treated with dsRNA targeting PTPRO, we found the ratio of PTPRO expression [left (or treated) side/right (or untreated) side] to be decreased by 29% relative to this ratio in untreated control embryos ( p Ͻ 0.05) (Fig. 3) . Thus, dsRNA treatment reduced PTPRO expression levels significantly. To evaluate the specificity of this result, we examined the relative levels of PTPon the two sides of spinal cords in control embryos and embryos treated with PTPRO dsRNA. In this case, the expression ratio was unchanged (5.5% increase; NS) (Fig. 3) . Thus, there is a specific decrease of the target RPTP (PTPRO) in embryos that are electroporated with PTPRO dsRNA.
We also tested knock-down of a second RPTP using dsRNA targeting PTP-; knock-down of PTP-protein was clearly seen in Western blots (Fig. 3) . Analysis of blots from three different experiments revealed that knock-down of PTP-protein averaged 25%, similar to what was seen with PTPRO dsRNA. Our results are consistent with previous experiments demonstrating specific knock-down of axonin-1 expression by the same protocol (Pekarik et al., 2003) . In this study, estimated knock-down averaged 28%, quantitatively similar to the present findings with PTPRO and PTP-. Together, the data suggest that our RNAi protocol specifically and effectively knocks down expression of the target RPTP. Because our evaluation of PTPRO and PTPknock-down is quantitatively consistent with axonin-1 knockdown, we expect that knock-down efficiency for PTP-␦ is similar; we could not test this directly because we lack a useful antibody to cPTP-␦.
It is important to note that knock-down of PTPRO in transfected neurons is underestimated by our Western blot data. First, only a fraction (Յ60%) of the cells on the treated side are transfected (Pekarik et al., 2003) . Thus, knock-down in transfected cells must be at least 50%. Second, by using the entire hemicord over the entire lumbosacral region, we are including tissue not likely to be efficiently electroporated. Finally, PTPRO is present in axons and growth cones (Bodden and Bixby, 1996; Stepanek et al., 2001) , and our samples will therefore contain axonal protein from neurons outside the targeted area. It is difficult to estimate the magnitude of the latter two effects, but our results with PTPRO-GFP suggest that knock-down is likely to be substantially more than 50%.
Knock-down of RPTPs produces a deficit in motor axon pathfinding PTP-␦, PTP-, and PTPRO have been shown to regulate neurite outgrowth in vitro (Ledig et al., 1999b; Wang and Bixby, 1999; Q. L. Sun et al., 2000; Stepanek et al., 2001) , and expression of putative dominant-negative constructs suggests that PTP-␦ and PTP-are involved in axon growth and guidance in the visual system (Johnson et al., 2001; Rashid-Doubell et al., 2002) . However, the involvement of these RPTPs in developmental axon guidance has not been tested by direct loss-of-function experiments in vivo. We used in ovo RNAi to examine loss-of-function phenotypes for these RPTPs in motor axon growth.
Embryos were electroporated with dsRNA targeting PTP-␦, PTP-, or PTPRO, and allowed to develop for 48 -60 h (to HH 26 -27). At HH 24 -26, motor axons diverge from the main nerve trunks and grow toward specific muscles (Hamburger, 1975 ; Op- A-C, Spinal cords were electroporated with PTPRO dsRNA or left untouched (Control). At E5, lumbosacral regions of the cords were dissected into left (treated) and right (untreated) halves, and pooled, and levels of PTPRO and control proteins were examined by Western blot. A, B, Representative blots of spinal cord lysates from left and right sides of experimental embryos. A, Blot probed with antibodies to PTPRO and to L1CAM. The PTPRO band at 180 kDa is fainter in the treated lysate, whereas the loading control (L1CAM; 90 kDa) is slightly stronger on the treated side. B, Blot probed with antibodies to PTP-and to L1CAM. The PTP-antibody recognizes two bands: the full-length form, PTP-2 at 150 kDa, and PTP-1 at 90 kDa. These bands are approximately equal in intensity between the untreated and treated sides, as is the L1CAM band. C, Band intensity was calculated using the Odyssey system. The ratio of left:right RPTP band intensity, normalized to L1CAM, is shown (mean Ϯ SEM). Control embryos have slightly more PTPRO and PTP-protein on the left side. Experimental embryos (dsPTPRO) show no change in relative PTP-levels, but 21.3% less PTPRO protein on the left side. n ϭ 3 for both control groups and dsPTPRO groups. *p Ͻ 0.05, two-tailed t test comparing PTPRO group with control. D, Spinal cords were electroporated with PTP-dsRNA; lumbosacral regions were dissected and subjected to Western blotting with antibodies to PTP-and to L1CAM. Whereas the L1 band is approximately equal in intensity on the two sides, both PTP-bands are fainter on the treated (left) side. The average decrease in protein on the treated side (normalized to L1) was 25% (n ϭ 3 experiments).
penheim and Heaton, 1975) . To evaluate the growth of peripheral nerves, we examined neurofilament staining in whole mounts of the lumbosacral region of the embryo. RNAi of RPTPs did not grossly affect the major nerve branches in the hindlimb (data not shown). However, knock-down of RPTPs resulted in a conspicuous phenotype in a superficial dorsal nerve (Fig. 4 A) . In control embryos, the untreated and treated nerves had three to four major bundles, with substantial lateral branching. In embryos treated with dsRNA targeting RPTPs, we saw changes in the morphology of this nerve on the treated side. In some cases, there were defasciculation errors such that the nerve had only one or two major bundles, and limited subbranching. In other cases, the nerve was much smaller, seeming to be delayed in its outgrowth, or was missing entirely.
To quantify these effects, we characterized embryos as "affected" (gross differences in the dorsal nerve between treated and untreated sides) or "unaffected" (only minor differences between the two sides) (see Materials and Methods) . Approximately 70% of embryos treated with dsRNA targeting either the PTP-␦ or PTP-were categorized as affected (Fig. 4 B) . Strikingly, Ͼ85% of embryos treated with dsRNA targeting the type III RPTP PTPRO were affected (Fig.  4 B) . These results suggest that the function of these RPTPs is essential for proper guidance of the axons in this dorsal nerve. We used several types of controls to determine the specificity of these effects. As controls for the experimental procedures, we examined embryos in which the egg was windowed but the embryo was left untouched, and embryos injected with PBS and electroporated. We also used controls to determine the specificity of the RNAi itself. First, embryos were electroporated with dsRNA targeting ChAT. ChAT is expressed in motor neurons at this time in development but does not appear to be necessary for initial axon outgrowth to muscle targets (Misgeld et al., 2002) . To control for the possibility that interference with any axon guidance cue would produce the phenotype we observed, we electroporated embryos with dsRNA targeting axonin-1. Axonin-1 is expressed in the axons of this dorsal nerve (Fig. 5A) . The dsRNA we used has been shown to knock down axonin expression and to cause clear and predictable defects in commissural axon pathfinding (Pekarik et al., 2003) . In none of the control situations did we observe more than ϳ20% affected embryos (Figs. 4 B , 5B). Indeed, RNAi for ChAT or axonin-1 produced no increase in affected embryos above that seen for PBS electroporation. Thus, knock-down of RPTPs specifically affects axonal morphology in this dorsal nerve.
To supplement our qualitative categorizations of embryos, we used several quantitative measures of phenotype. A computer algorithm designed to delineate nerve from background (see Materials and Methods) counted pixels in images of each nerve. This gave us an estimate of nerve area, which we used to calculate a ratio of treated nerve area to untreated nerve area (Fig. 6) . In control embryos, the mean ratio was slightly larger than 1; in PBS and ChAT embryos, the mean ratio was ϳ0.9. Embryos electroporated with dsRNA targeting PTP-␦ or PTPhad a ratio of 0.7. Remarkably, embryos electroporated with dsRNA targeting PTPRO had nerves that were on average only one-half as large as those of controls; this difference was highly statistically significant. Similar results were obtained using the Neurolucida program to calculate total nerve length from traced images. Embryos treated with dsRNA targeting PTPRO had significantly shorter treated nerves than ChAT control embryos ( p Ͻ 0.001); PTP-␦ and PTP-embryos also showed a decrease Spinal cords were electroporated with dsRNA targeting ChAT (n ϭ 16), Axonin-1 (Ax-1; n ϭ 16), PTP-(n ϭ 30), PTP-␦ (n ϭ 27), or PTPRO (n ϭ 37) and allowed to develop for 2 d before fixation and fluorescent staining with anti-neurofilament. Control embryos (n ϭ 25) were only windowed, and PBS embryos (n ϭ 19) were electroporated with PBS. A, Representative photomicrographs showing dorsal views of whole-mount embryos treated with PBS (left 2 panels) or PTPRO dsRNA (right 2 panels). The left (treated) dorsal nerve was visually compared with the right (untreated) dorsal nerve (arrowheads). Embryos were categorized as unaffected (u) or affected (a); affected embryos had much smaller or missing nerves (top), or showed major changes in fasciculation and branching (bottom). Scale bar, 0.5 mm. B, Quantification of dorsal nerve effect. The percentage of affected embryos is shown for each treatment group. Eighty to 100% of control embryos [control (Con), PBS, ChAT, Ax-1] fall into the unaffected category. However, the majority of embryos treated with dsRNA targeting the RPTPs were affected. A two-sided Fisher's exact test was used to compare treatment groups with ChAT. *Significantly different, p Ͻ 0.01. ***Significantly different, p Ͻ 0.001. The most severely affected phenotypes (missing or greatly truncated nerves) were never seen with untouched, PBS, ChAT, or axonin-1 embryos; percentages of severely affected embryos were as follows: PTP-, 23%; PTP-␦, 26%; PTPRO, 49% (data not shown).
in nerve length on the treated side but were not significantly different from control.
Analysis of nerve branching (number of primary branches on control and treated sides) demonstrated a significant effect of knocking down each of the RPTPs we tested. Embryos treated with dsRNA targeting PTP-had an average of 3.2 Ϯ 0.2 primary branches on the untreated side, but only an average of 2.0 Ϯ 0.2 primary branches on the treated side ( p ϭ 0.0001; Wilcoxon matched-pairs t test). Embryos treated with dsRNA targeting PTP-␦ or with PTPRO had an average of 2.8 Ϯ 0.1 primary branches on the untreated sides compared with 2.1 Ϯ 0.2 and 2.0 Ϯ 0.2 primary branches on the treated sides, respectively ( p Ͻ 0.01 and p Ͻ 0.001). In contrast, control embryos treated with dsRNA targeting ChAT had an average of 2.9 Ϯ 0.2 primary branches on both the untreated and treated side. Overall, our quantitative description of the phenotype followed the same pattern as that of our qualitative data; knock-down of each of the three RPTPs changed the size and morphology of the treated nerve, although interference with PTPRO had the greatest effect in our experiments. These data suggest that type IIa and type III RPTPs are involved in axon pathfinding by chick motor neurons. The effect we saw with PTPRO knock-down represents the first evidence for an in vivo role of a type III RPTP in vertebrate axon growth.
The affected dorsal nerve is the anterior iliotibialis
To identify the dorsal nerve affected by RPTP knock-down, we followed the projection pattern of this nerve during development by neurofilament staining of embryos at HH 29 -32 (E6 -E7.5) (data not shown). Over time, the nerve spreads as a thin sheet covering the lateral surface of the thigh. This pattern corresponds to the position of the anterior iliotibialis, a thin, sheet-like muscle that contains both fast-and slow-twitch muscle fibers (Landmesser, 1978a; Milner et al., 1998) . To confirm this identification, we used retrograde DiI labeling in E5.5 embryos to identify the neurons of origin of the dorsal nerve. We found that the motor portion of the nerve arises from neurons in the lateral portion of the ventral horn in lumbosacral segments (LS) 1-3 (Fig. 7) . This is fully consistent with the position of the anterior iliotibialis motor neuron pool (Landmesser, 1978a) . Based on the position and projection pattern of the dorsal nerve, and the position of the motor neurons giving rise to this nerve, we will refer to it as the AITIB. PTPRO mRNA is found in, but is not limited to, neurons of the E5 ventral motor column in which the AITIB motor pool is found (Figs. 1, 7B ) (data not shown). Thus, PTPRO appears to be expressed in the motor neuron pool that gives rise to the AITIB during the time of AITIB outgrowth. Sensory neurons were also labeled by the retrograde tracing (Fig. 7B, inset) , showing that the affected AITIB is a mixed nerve.
To examine the effects of RNAi on individual motor axons, we performed anterograde DiI tracing. DiI was placed in the lateral portion of the ventral horn in vibratome sections from LS 1-3 of embryos electroporated with dsRNA targeting PTPRO, and tracing was examined using a confocal microscope. Because of limitations on the thickness of sections suitable for this type of microscopy, the entire length of the AITIB was rarely identified. However, we consistently observed that labeled motor axons on the treated side of the embryo (Fig. 8 A) were shorter than those on the untreated side of the embryo ( B). We did not observe differences in motor axon trajectories within the spinal cord or the plexus region. Thus, these experiments indicate that AITIB motor axon growth is retarded by knock-down of PTPRO. 
The AITIB phenotype is not caused by increased death of motor neurons
If in ovo RNAi of RPTPs led to increased motor neuron death, this could contribute to a reduction in the size of the AITIB. To investigate this possibility, we counted the number of motor neurons in embryos electroporated with PTPRO dsRNA. Serial sections from PTPRO or control embryos were stained with an antibody to the transcription factor Isl-2, an early marker for motor neurons (Tsuchida et al., 1994) . Isl-2-positive cells were counted using design-based stereology (see Materials and Methods) in treated and untreated sides of spinal cord lumbosacral segments 1-5. Similar numbers of Isl-2-positive cells in individual sections were seen in both PTPRO RNAi embryos and in controls (Fig. 9) . Additionally, the estimates of total motor neurons in the entire volume examined were similar between the two sides of the embryos. The ratio of Isl-2-positive cells in treated compared with untreated spinal cord halves was 0.98 Ϯ 0.02 for control embryos, and 0.99 Ϯ 0.01 for PTPRO RNAi embryos (n ϭ 3 for both groups). Thus, cell death of motor neurons does not contribute substantially to the mean 50% decrease in AITIB size in PTPRO-targeted embryos. (Desai et al., 1997; Q. Sun et al., 2000; Schindelholz et al., 2001) . Do vertebrate RPTPs also interact in the regulation of motor axon pathfinding? To answer this question, we used combinatorial RNAi. It has been demonstrated that several genes can be silenced together by injecting a combination of dsRNAs targeting the genes of interest, if the RNAs are injected at reasonably high concentrations (Schmid et al., 2002) . For our experiments, we first determined that 500 ng/l was the dsRNA concentration that produced the most reliable PTPRO phenotype (data not shown). In the combination experiments, we therefore used all of the dsRNAs at a final concentration of 500 ng/l.
Embryos in which both type IIa RPTPs (PTP-␦ and PTP-) were targeted had approximately the same severity of phenotypes as embryos in which either PTP-␦ or PTP-alone were targeted, although the percentage affected was slightly higher in the combination experiments than for either RPTP alone (Fig. 10 A) . These data provide no evidence for a strong interaction between PTP-␦ and PTP-in the growth of the AITIB.
Embryos in which either PTP-␦ or PTP-was targeted concomitantly with the type III RPTP, PTPRO, were on average less severely affected than embryos in which PTPRO alone was targeted ( Fig. 10 B) . In the case of PTPRO/PTP-␦, only 50% of embryos were classified as affected, compared with 87% for PTPRO alone, a significant reduction ( p Ͻ 0.01). To ensure that this reduction in phenotype severity was not simply attributable to addition of a second dsRNA, we used a combination of PTPRO and ChAT dsRNAs. A slight and nonsignificant reduction in the percentage of affected embryos was seen in this case, indicating that the reduction in phenotype severity seen with PTPRO/ PTP-␦ was specific to this combination. These data suggest that PTPRO and PTP-␦ compete functionally during the growth of the AITIB nerve. A similar trend was seen for PTP-/PTPRO, but the data do not allow a conclusion in this case.
Finally, we tested a combination of dsRNAs targeting all three RPTPs (Fig. 10C) . In this case, the reversion of the PTPRO phenotype was even more dramatic, with only 41% of the embryos categorized as affected ( p Ͻ 0.01). As a control for the use of large amounts of dsRNA, we tested PTPRO dsRNA in conjunction with 1000 ng/l ChAT dsRNA; no significant difference was seen compared with PTPRO alone. These data suggest that PTP-␦, together with PTP-, counteracts the role of PTPRO in controlling the outgrowth of the AITIB. The need to balance the functional activities of type IIa and type III RPTPs in motor axon guidance is similar to the situation in Drosophila. The data may indicate a conserved function for RPTPs in motor axon outgrowth from flies to vertebrates.
Discussion
RNAi targeting of PTP-␦, PTP-, or PTPRO in spinal motor neurons led to dramatic changes in the morphology of the developing AITIB nerve. Although RNAi produced similar changes for all of the RPTPs examined, knock-down of the type III RPTP PTPRO produced the strongest effects. Knock-down of the type IIa RPTPs in combination with PTPRO suggests competition among these RPTPs in axon guidance. Notably, our results provide the first evidence implicating a type III RPTP in vertebrate axon pathfinding. (arrowhead) . B, Retrograde labeling from the dorsal nerve labels neurons in the ventrolateral region of the lumbar enlargement. A single neuron is in focus; its axon can be seen leaving the cord, and its dendrites extend some distance medially and laterally (arrowhead). The position of labeled neurons is consistent with the location of the AITIB motor neuron pool (Milner et al., 1998) . Inset, In another section, both motor (arrowhead) and sensory (arrow) neurons are labeled by the retrograde tracing. Scale bars, 100 m. Anterograde tracing is apparent in the AITIB at a greater distance from the ventral horn in the untreated side of the embryo (B) than in the treated side (A). This was a consistent finding after PTPRO knock-down (n ϭ 6 embryos) and was not seen with control injections (n ϭ 7 embryos). Arrowheads indicate the plexus region where the AITIB turns to grow dorsally. Scale bar, 100 m. . Control experiments in which PTPRO was combined with a 2ϫ concentration of dsChAT RNA (n ϭ 21) produced no significant change in the number of affected embryos compared with PTPRO alone, indicating that the effect of the RPTP knock-down is specific and not attributable to dilution of PTPRO dsRNA by other dsRNA.
